The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced ...

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic ...